BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22955113)

  • 1. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
    Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
    Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
    Huber-Wechselberger AE; Niedetzky P; Aigner I; Haschke-Becher E
    Wien Med Wochenschr; 2012 Jun; 162(11-12):252-61. PubMed ID: 22688624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
    Dieudonné AS; Lambrechts D; Smeets D; Belmans A; Wildiers H; Paridaens R; Hyonil C; Timmerman D; Christiaens MR; Vergote I; Neven P
    Ann Oncol; 2014 Jan; 25(1):90-5. PubMed ID: 24265353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
    Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
    Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
    Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
    Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
    Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
    Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen and CYP2D6: a contradiction of data.
    Hertz DL; McLeod HL; Irvin WJ
    Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.
    Bezerra LS; Santos-Veloso MAO; Bezerra Junior NDS; Fonseca LCD; Sales WLA
    Rev Bras Ginecol Obstet; 2018 Dec; 40(12):794-799. PubMed ID: 30536272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
    Barrière J; Formento JL; Milano G; Ferrero JM
    Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 polymorphisms and the impact on tamoxifen therapy.
    Beverage JN; Sissung TM; Sion AM; Danesi R; Figg WD
    J Pharm Sci; 2007 Sep; 96(9):2224-31. PubMed ID: 17518364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.